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In May 2000, the 3M Company (3M)
announced that it would voluntarily cease
manufacturing materials based on perﬂuoro-
octanesulfonyl fluoride (POSF; C8F17SO2F)
after a metabolite of this compound, per-
fluorooctanesulfonate (PFOS; C8F17SO3
–),
was found to be widespread in human popu-
lations and wildlife (3M Company 2003;
Giesy and Kannan 2001; Hansen et al. 2001;
Kannan et al. 2001a, 2001b, 2002a, 2002b).
Using POSF as a basic building block, unique
chemicals were created by further reactions
with functionalized hydrocarbon molecules.
Major applications of these POSF-based prod-
ucts have included surfactants, paper and pack-
aging treatments, and surface protectants (e.g.,
for carpet, upholstery, textile). Depending on
the specific functional derivatization or the
degree of polymerization, such POSF-based
products may degrade or metabolize, to an
undetermined degree, to PFOS, a stable and
persistent end product that has the potential to
bioaccumulate. Although not a major com-
mercial product, PFOS has been used in some
products, including ﬁre-ﬁghting foams.
The mechanisms and pathways leading to
the presence of PFOS in human blood are not
well characterized but likely involve environ-
mental exposure to PFOS or to precursor
molecules and residual levels of PFOS or
PFOS precursors in industrial and commercial
products. PFOS has been detected at low parts
per billion (nanogram per milliliter) concentra-
tions in the general population (3M Company
2003; Hansen et al. 2001; Olsen et al. 2003b),
although the scope and sample size of these
investigations have been limited. Serum PFOS
concentrations among production employees
working in POSF-related processes have aver-
aged between 0.5 and 2 ppm depending on
work activity (range < 0.1–12 ppm) (Olsen et
al. 1999, 2003a, 2003c). A large body of toxi-
cology and epidemiology data is available for
review regarding PFOS [3M Company 2003;
Organisation for Economic Co-operation and
Development (OECD) 2002]. Results from
several repeat-dose toxicologic studies consis-
tently demonstrated that the liver is the pri-
mary target organ (3M Company 2003;
OECD 2002). Liver cell hypertrophy and
reduction in serum cholesterol are early
responses to PFOS that occur in rats as well as
monkeys. Both species display an apparent
threshold for the toxic effects of PFOS that can
be expressed in terms of cumulative dose or
body burden, with no observable response at
lower cumulative doses or body burdens.
Following the company’s announcement to
voluntarily cease production, the U.S.
Environmental Protection Agency (EPA) ﬁnal-
ized a significant new use rule to regulate
PFOS and related chemicals (U.S. EPA 2002).
The purpose of this study was to better
characterize the distribution of PFOS and six
other fluorochemicals, some of which are
PFOS precursors, in a large adult population
by analyzing serum samples obtained from
donors at six American Red Cross blood
banks. An assessment of the serum fluoro-
chemical distribution was performed in rela-
tion to three demographic attributes (age, sex,
and location) of the anonymous blood donors.
Materials and Methods
Fluorochemicals
The seven analytes detected and quantified
in this study were PFOS, N-ethyl perﬂuoro-
octanesulfonamidoacetate [PFOSAA;
C8F17SO2N(CH2CH3)CH2COO–],
N-methyl perﬂuorooctanesulfonamidoacetate
[M570; C8F17SO2N(CH3)CH2COO–],
perfluorooctanesulfonamidoacetate (M556;
C8F17SO2NHCH2COO–), perﬂuorooctane-
sulfonamide (PFOSA; C8F17SO2NH2), per-
fluorooctanoate (PFOA; C7F15COO–), and
perﬂuorohexanesulfonate (PFHS; C6F13SO3
–).
PFOSAA is an oxidation product of
N-ethyl perfluorooctanesulfonamidoethanol
(N-EtFOSE), which was primarily used in
paper and packaging protectant applications.
M570 is an oxidation product of N-methyl
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Perfluorooctanesulfonyl fluoride-based products have included surfactants, paper and packaging
treatments, and surface protectants (e.g., for carpet, upholstery, textile). Depending on the speciﬁc
functional derivatization or degree of polymerization, such products may degrade or metabolize, to
an undetermined degree, to perﬂuorooctanesulfonate (PFOS), a stable and persistent end product
that has the potential to bioaccumulate. In this investigation, a total of 645 adult donor serum sam-
ples from six American Red Cross blood collection centers were analyzed for PFOS and six other
ﬂuorochemicals using HPLC-electrospray tandem mass spectrometry. PFOS concentrations ranged
from the lower limit of quantitation of 4.1 ppb to 1656.0 ppb with a geometric mean of 34.9 ppb
[95% conﬁdence interval (CI), 33.3–36.5]. The geometric mean was higher among males (37.8 ppb;
95% CI, 35.5–40.3) than among females (31.3 ppb; 95% CI, 30.0–34.3). No substantial difference
was observed with age. The estimate of the 95% tolerance limit of PFOS was 88.5 ppb (upper limit
of 95% CI, 100.0 ppb). The measures of central tendency for the other ﬂuorochemicals (N-ethyl
perﬂuorooctanesulfonamidoacetate, N-methyl perﬂuorooctanesulfonamidoacetate, perﬂuorooctane-
sulfonamidoacetate, perﬂuorooctanesulfonamide, perﬂuorooctanoate, and perﬂuorohexanesulfonate)
were approximately an order of magnitude lower than PFOS. Because serum PFOS concentrations
correlate with cumulative human exposure, this information can be useful for risk characterization.
Key words: American Red Cross, biomonitoring, blood donors, ﬂuorochemicals, perﬂuorooctane-
sulfonate, perfluorooctanoate, PFOA, PFOS. Environ Health Perspect 111:1892–1901 (2003).
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was used primarily in surface treatment appli-
cations (e.g., carpets, textiles). Therefore,
PFOSAA and M570 can be considered mark-
ers of consumer-related exposure. Both
PFOSAA and M570 can metabolize to M556
and PFOSA, which in turn can later metabo-
lize to PFOS. Unlike PFOSAA and M570,
other POSF-related analytes (M556, PFOSA,
and PFOS) are not specific to any one con-
sumer application. PFOA and PFHS are not
precursors or metabolites of PFOS. Ninety-
seven percent of PFOA that was produced by
3M was used by its industrial customers and
in its own processes as a fluoropolymer pro-
cessing aid (Wendling 2003). The remainder
was used in medical film coating and elec-
tronic applications involving printed circuit
boards and precision bearings. 3M analytical
studies of eight POSF-based product samples
have identiﬁed the presence of PFOA at very
low concentrations as a manufacturing impu-
rity (Wendling 2003). In a biodegradation
study of N-EtFOSE, PFOA could be formed
instead of PFOS only under an abiotic or
hydrolytic condition during the last step of the
degradation pathway (Lange 2001). PFOA
could also be an oxidation product or metabo-
lite of the widely used telomer-based fluoro-
chemicals manufactured by other companies
(Hagen et al. 1981). PFHS, the sulfonate form
of perfluorohexanesulfonyl fluoride (PHSF),
could also be a residual by-product of POSF-
based production. 3M also produced PHSF as
a building block for compounds incorporated
in ﬁre-ﬁghting foams and speciﬁc postmarket
carpet treatment applications.
We also calculated the total organic ﬂuo-
rine value (TOF). TOF is the percentage of
the molecular weight for each of the seven
ﬂuorochemicals that was attributed to organic
fluorine (PFOS, 64.7%; PFHS, 61.9%;
PFOA, 69.0%; PFOSAA, 55.3%; PFOSA,
64.7%; M570, 56.6%; M556, 58.1%) multi-
plied by the concentration measured for each
fluorochemical and then summed across all
seven ﬂuorochemicals.
Sample Collection
Through cooperation with six American Red
Cross blood banks, 645 serum samples (332
males, 313 females) were obtained from adult
donors (20–69 years of age) in 2000–2001.
Each sample (1–2 mL serum) was stored at
–20°C in a plastic tube until laboratory analy-
sis. Methodologic studies have not shown these
fluorochemicals to be extracted from blood
collection materials (Hansen K. Personal com-
munication). The six American Red Cross
blood banks represented donors from the fol-
lowing areas: Los Angeles, California; Portland,
Oregon; Minneapolis–St. Paul, Minnesota;
Charlotte, North Carolina; Hagerstown,
Maryland; and Boston, Massachusetts. These
metropolitan areas were chosen to represent
different geographical locations in the United
States. (The primary 3M POSF-based produc-
tion facility in the United States was located in
Decatur, AL, which is not in the area of any of
these six locations. 3M did manufacture PFOA
at its Cottage Grove, MN, plant, which is
located in the southeastern part of the
Minneapolis–St. Paul metropolitan area. At
this site there was also some production of
POSF-based materials but not to the same
extent as manufactured at the Decatur plant.)
Approval for this study was obtained from
the American Red Cross Biomedical Services
Institutional Review Board. Samples were void
of personal identiﬁers. The only known demo-
graphic factors were age, gender, and location.
Each blood bank center was requested to pro-
vide approximately 100 serum samples: 10
samples for each 10-year age interval (20–29,
30–39, 40–49, 50–59, and 60–69) for each sex.
We estimated a priori a statistical power of
more than 95% to detect a 20% difference
between any two 10-year age groups (combined
locations) and more than 80% power to detect
a 20% difference by sex within each age group.
Laboratory Assay
Tandem Labs (formerly Northwest
Bioanalytical; Salt Lake City, UT) analyzed
the fluorochemicals using techniques similar
to those described by Hansen et al. (2001).
Some modiﬁcations were made to the method
to accommodate the small sample volume and
to further assure the quality of the method for
the analysis of human sera and plasma samples
(Tandem Labs 1999, 2001a, 2001b).
Sample preparation. One hundred micro-
liters of serum (or plasma) were extracted for
analysis. The serum sample was added to
400 µL of 50 mM ammonium acetate in
water in a polypropylene tube. Samples were
vortex mixed and 50 µL of the internal stan-
dard, tetrahydroperfluorooctanesulfonate
(THPFOS), was added to each sample before
a second vortex mixing of approximately
30 sec. Three milliliters of methyl-tert-butyl
ether (MTBE) was then added to each sample,
which was vortex mixed for 30 sec and rotated
for 10 min. The samples were centrifuged,
and the MTBE layer was transferred to a clean
polypropylene tube. The MTBE was evapo-
rated to dryness, and the extract was reconsti-
tuted in 100 µL 30:70 (vol:vol) 20 mM
ammonium acetate in water:20 mM ammo-
nium acetate in methanol and vortex mixed
for 15 sec. The samples were transferred to
autovials and centrifuged at 3,000 rpm for
2 min.
Because of the difﬁculty in ﬁnding suitable
human sera in the United States to use for
method blanks and quality control (QC) sam-
ples, we obtained rural Chinese human plasma,
collected in 1999, with low endogenous 
ﬂuorochemical concentrations, from a source
within the United States. Studies designed to
characterize the selectivity and the extraction
efficiency for the two matrices, conducted
before the sample analysis, indicated that this
plasma was a suitable choice for the calibration,
blank, and QC matrix samples.
Blank samples were prepared in the same
way as the sera samples. The internal standard
solution was added to half of the blank plasma
samples; the remaining plasma blanks were
prepared without internal standard. The THP-
FOS internal standard was added to all plasma
and serum samples at approximately 200 ppb.
THPFOS is a partially ﬂuorinated surfactant
with a structure similar to the target analytes
and is a reasonable surrogate for all the analytes
in this study. Studies carried out before valida-
tion indicated that, because THPFOS has a
retention time very similar to PFOA, extremely
high levels of PFOA (> 500 ppb) can suppress
the signal for THPFOS, resulting in artiﬁcially
high reported levels of all analytes except
PFOA. However, none of the samples analyzed
in this study contained PFOA at high enough
levels to suppress the THPFOS signal.
Calibration standards and QC samples,
extracted from plasma, were prepared follow-
ing the same procedure described for the sam-
ples except that the QC standards were spiked
with a mixture of the seven target analytes
concurrent with the addition of the internal
standard.
Given the low-level presence of many of
the target analytes in these biologic matrices,
rigorous attention to the preparation, analysis,
and data interpretation of blanks, calibration
standards, and QC samples was critical. The
analytical system was monitored for analytical
artifacts such as carryover and for potential
sources of contamination.
Analysis of samples. We used a Genesis
Lightning C18 4-µm inner diameter, 2 ×
50 mm analytical column (Argonaut
Technologies, Inc., Foster City, CA) for chro-
matographic separation. The mobile phase
was 20 mM ammonium acetate in water (a)
and 20 mM ammonium acetate in methanol
(b) and was programmed to run from 50% to
97.5% (b) over the course of a 9-min gradient.
After a 2-min hold at 97.5% (b), the run equi-
librated back to 50% (b) for 2 min. The ﬂow
rate was 300 µL/min and the column was
maintained at 40°C. 2-(2-Methylethoxy)-
ethanol (50 µL/min) was added postcolumn.
Extracts were analyzed on a Perkin-Elmer
Sciex API3000 with a TurboIon Spray source
(PE Sciex, Concord, Ontario, Canada) main-
tained at 400°C in the negative ion mode. All
seven target analytes, along with the internal
standard, were monitored in a single run
recording a single transition for each ion with
a dwell time of 70 msec. The collision energy
was optimized for each analyte and ranged
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work was quantitation of the total amounts of
the target analytes, isomers of the target ana-
lytes were treated as a single peak even though
full resolution was achieved. Quantitation was
based on evaluation of the samples versus
duplicate calibration curves extracted from
plasma predetermined to contain little or no
endogenous levels of the target analytes. The
calibration curves were evaluated using a qua-
dratic regression analysis (weighted 1/X2).
Method characterization and QC. Before
analysis of the samples, we validated this
method with respect to selectivity, accuracy,
precision, quantitation range, and lower limit
of quantitation (LLOQ). The extraction efﬁ-
ciency of the target analytes from human
serum was between 15% and 70%, depending
on the analyte. It was not necessary to correct
for extraction efﬁciency because the calibration
curve was extracted. The precision and accu-
racy of the method were determined for all
analytes by analyzing three levels of QC sam-
ples in replicates of ﬁve in a single run. Intra-
assay precision was within 6% for all analytes;
the accuracy was ± 18% for all analytes.
The LLOQ, evaluated for each run and
analyte, varied between 1 and 4 ppb. We did
not perform an experimental determination of
the method LLOQ; instead, the lowest stan-
dard injected for a particular run that met the
acceptance criteria was chosen as the LLOQ.
Samples were evaluated quantitatively using a
6–8-point extracted calibration curve covering
the target range for each analyte from about 1
to 500 ppb. For all analytes except PFOSA and
PFOSAA, at least 75% of the back-calculated
concentrations for the calibration standard was
required to be within 15% (20% at LLOQ) of
the theoretical concentration. For PFOSA and
PFOSAA, at least 75% of the back-calculated
concentrations for the calibration standard was
required to be within 20% (25% at LLOQ) of
the theoretical concentration.
We found that QC samples, calibration
standards, and samples were stable through
seven freeze–thaw cycles. All analytes were
stable in matrix through 42 days at –20°C.
All analytes were stable in the extracts
through 7 days stored at room temperature.
Analytical QCs, extracted from plasma
and prepared at the same time as the calibra-
tion curve, were injected intermittently during
the analytical run. Three levels of QC samples,
spanning the range of the method (~4, 150,
and 400 ppb), were analyzed in duplicate.
Analytical QCs were analyzed in duplicate;
dilution QCs were also prepared and analyzed
and run in triplicate for any assay that con-
tained a diluted sample. QC samples were pre-
pared at three levels spanning the calibration
range: approximately 4, 150, and 400 ppb.
The measured concentration for two-thirds of
all analytical QCs was required to be within
20% (25% for PFOSA and PFOSAA) of the
theoretical concentration, and no two QCs at
the same concentration could be outside the
limit. Any analytical run containing a diluted
sample included a dilution QC, analyzed in
triplicate for each dilution level. At least two
of the dilution QCs were required to be
within 20% of the theoretical concentration.
Evaluation of QC samples injected during the
analytical runs of the 645 samples indicated
that the reported quantitative results may have
varied ± 10% for precision and accuracy
(Tandem Labs 2002).
Twenty-four samples were split and ana-
lyzed to provide an estimate of the reliability
of the analyses conducted. The analytical lab-
oratory was blind to the identity of these split
samples. These analyses were performed con-
currently with all other analyses of the study
to minimize experimental error. Five split
samples were analyzed from Charlotte, Los
Angeles, Hagerstown, and Portland and four
split samples from Boston. Inadvertently, no
reliability analyses were performed on the
Minnesota samples. There was a strong corre-
lation between the split samples (r = 0.9) with
PFOS, PFOA, and PFHS. The analysis of the
split samples for the other fluorochemicals
was problematic because only six split samples
for PFOSAA and seven split samples for
M570 had values that were above the LLOQ.
None of the PFOSA and M556 split samples
were above the LLOQ.
Data Analysis
We used measures of central tendency applic-
able to log-normally distributed data (median,
geometric mean) for descriptive analyses. In
those instances where a sample was measured
below the LLOQ, the midpoint between zero
and the LLOQ was used for calculation of the
geometric mean. A sensitivity analysis of the
assessment of this midpoint assumption and
how it affected the calculation of the geo-
metric mean was performed using the 10th
and then 90th percentile values between zero
and the LLOQ for those samples < LLOQ.
Results for the geometric mean calculations
for each fluorochemical remained similar to
when the midpoint assumption was used
(data not shown).
The log-linear relation between PFOS
and PFOA was modeled as follows:
ln[PFOS] = (a × ln[PFOA]) + (c × age) 
+ (d × sex) + (f × age × sex) 
+ g + ε, [1]
where g is the intercept and ε is the error
term. We used an analogous log-linear model
to relate PFOS to PFHS. The interaction
term between age and sex was not a signifi-
cant predictor in either model and was there-
fore not included in the final analyses.
Residuals were inspected to assure model
assumptions provided reasonable ﬁt.
To examine the relationship between PFOS
concentration and the concentration of the two
other precursor molecules, PFOSAA and
M570, a nonlinear model was ﬁt to the data:
ln[PFOS] = ln([PFOSAA]a + [M570]b)
+ (c × age) + (d × sex) 
+ (f × age × sex) + g + ε. [2]
This model represents an additive relation
between PFOS concentration and the concen-
trations of the other two molecules because the
hypothesized mechanisms of association—that
is either correlated exposure sources or conver-
sion from one molecule to another—suggested
additivity rather than a multiplicative relation.
At the same time, the model is consistent with
the simpler models relating PFOS concentra-
tion to that of a single molecule and preserves
the log-linear relationship of PFOS concentra-
tion to age and sex suggested by inspection of
the residuals in these simpler models. The
adjusted log-linear models were ﬁt using maxi-
mum likelihood using the lm program, and the
adjusted nonlinear model was fit using
weighted nonlinear least squares, as imple-
mented in the nls program; both are programs
in S-Plus, version 6.0 (Insightful Corporation
2001). To avoid making normality assump-
tions in these log-linear models, bootstrapping
was used to form conﬁdence intervals for the
parameters (Efron and Tibshirani 1993). In
this method, a large number of full-size sam-
ples of the original observations are drawn with
replacement, from each of which an estimate
of the percentile is generated. The distribution
of these estimates mimics the underlying sam-
pling distribution for the original estimate
assuming that the parent population looks like
the sample. We used bias-corrected, acceler-
ated percentiles to minimize residual bias. A
bias correction factor is derived by comparing
empirical percentiles with bootstrap per-
centiles, and acceleration is accomplished by
partial jackkniﬁng, a method of systematically
resampling the data. The effect on parameter
estimates and conﬁdence intervals of includ-
ing location as a random effect in the above
models (using the S-Plus programs lme and
nlme) was negligible; only the results from the
nonhierarchical models are given. In order to
minimize parametric assumptions in the esti-
mation of extreme percentiles of the popula-
tion, the bias-corrected, accelerated bootstrap
method was also used to generate conﬁdence
intervals around the empirical percentiles for
serum concentrations.
Results
The frequency distributions of PFOS, PFOA,
PFHS, PFOSAA, and M570 are shown in
Figure 1. Although the graphs suggest 
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distribution met such criteria based on the
Shapiro-Wilk test. This lack of log normality
is due to the greater percentage of subjects
with values < LLOQ for PFOA, PFHS,
PFOSAA, and M570. Statistical analyses are
not presented for PFOSA and M556 because
of the low number of subjects (n = 13) whose
serum concentrations of PFOSA or M556
exceeded the LLOQ. The LLOQs for PFOSA
and M556 ranged between 1.0 and 3.2 ppb.
Although PFOSA and M556 are not presented
in the later analyses, they were included in the
calculation of the TOF value assuming the
midpoint between zero and the LLOQ.
The range, interquartile range (IQR; i.e.,
the lower end of the second quartile and the
upper end of the third quartile), number of
samples < LLOQ, 90th percentile, median,
geometric mean, and 95% conﬁdence interval
(CI) of the geometric mean for PFOS, PFOA,
PFHS, PFOSAA, and M570 are provided in
Table 1. The midpoint assumption was based
on the LLOQs in place for the speciﬁc sample
runs. No donor sample had more than one
LLOQ. The percentages of samples < LLOQ
for each fluorochemical were PFOS, 0.2%;
PFOA, 8%; PFHS, 48%; PFOSAA, 58%;
and M570, 60%.
For all donors, the geometric mean PFOS
level was 34.9 ppb (95% CI, 33.3–36.5). The
range of PFOS values was < LLOQ (4.3 ppb)
to 1656.0 ppb. Serum samples from male sub-
jects had significantly (p < 0.05) higher geo-
metric means for PFOS than for serum
samples from female subjects (Table 1). Serum
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Figure 1. Adult study population distributions of measured
serum fluorochemical concentrations for (A) PFOS, (B) PFOA,
(C) PFHS, (D) PFOSAA, and (E) M570. LOQ, limit of quantitation.samples from males also had significantly
higher serum levels of PFOA and PFHS com-
pared with serum samples from females,
although the mean levels for both sexes were
approximately one order of magnitude lower
than that of PFOS. The overall geometric
mean for the calculated TOF was 31.7 ppb
(95% CI, 30.4–33.0; data not shown). The
calculated TOF values ranged from 5.7 ppb to
1083.2 ppb.
Age was not an important predictor of
adult serum fluorochemical concentrations
(Figure 2). Instances of many outliers (e.g.,
M570 concentrations in males 40–49 and
60–69 years of age) occurred as a result of a
large percentage of values < LLOQ that were
within the 1.5 × interquartile range.
The unadjusted (for age and sex) serum
PFOS concentrations were higher in Charlotte
compared with the other locations as a conse-
quence of a higher interquartile range
(Table 2). Table 3 shows the results from the
statistical bootstrap analysis that calculated
mean serum ﬂuorochemical values for each of
the six locations adjusted for 10-year age inter-
vals, sex, and their interaction terms. There was
a 10-ppb difference in the adjusted mean serum
PFOS concentration between the highest
(Charlotte) and lowest (Boston) locations. The
mean values for the other ﬂuorochemicals were
comparable between locations. Because PFOS
is the primary contributor to the calculated
TOF, the bootstrap analysis ﬁndings for TOF
mirrored those of PFOS.
Scatter plots (log scale) between the five
fluorochemicals are displayed in Figure 3.
PFOS and PFOA were highly correlated
(r = 0.63). PFOS had a lower correlation with
PFOSAA (r = 0.42) and lower yet with M570
(r = 0.20). The correlation between PFOSAA
and M570 was weak (r = 0.12). The remaining
scatter plots display the correlations between
PFOS and PFHS (r = 0.38) and PFOA and
PFHS (r = 0.32).
Both PFOSAA and M570, adjusted for age
and sex, were signiﬁcant predictors of PFOS
(Table 4). PFOSAA was the more signiﬁcant
of the two variables (PFOSAA t-value = 14.5;
M570 t-value = 4.6). Controlling for age and
sex, PFOA and PFHS were also associated
with PFOS.
Table 5 presents the results from bootstrap
analyses conducted to provide upper tolerance
limits. The upper tolerance limits represent
the concentration of each fluorochemical
below which the stated proportion of the pop-
ulation is expected to be found. The biased
corrected estimates for the 90th, 95th, and
99th percentile tolerance limits of the five
serum fluorochemicals and TOF along with
the upper limit (bound) from the 95% CI are
shown in Table 5.
Discussion
The findings from this analysis of serum
PFOS concentrations in 645 adult blood
donors are consistent with previous, albeit
sparse, human data (3M Company 2003;
Hansen et al. 2001; Olsen et al. 2003b).
Serum samples obtained in the United States
during the late 1990s showed mean PFOS
concentrations of 30 ppb in 18 pooled blood
banks, 44 ppb from a pooled commercial sam-
ple of 500 donors, 33 ppb from a different
pooled commercial sample of 200 donors,
and 28 ppb in 65 commercial individual
human sera samples (3M Company 2003;
Hansen et al. 2001). These ﬁndings were also
comparable to a limited number of serum
samples from Europe that were determined to
have mean serum PFOS concentrations at
17 ppb in five pooled samples from a blood
bank in Belgium, 53 ppb in six pooled sam-
ples from the Netherlands, and 37 ppb from
six pooled blood samples from Germany (3M
Company, 2003). Mean liver and serum
PFOS concentrations of 20.8 ng/g (ppb) and
18.2 ng/mL (ppb), respectively, were reported
among 23 human donors with paired samples
(Olsen et al. 2003b). The mean calculated
TOF of 31.7 ppb in the present study is also
consistent with the low–parts-per-billion
TOF measurements of general population
samples that have been reported since the
1960s (Belisle 1981; Singer and Ophaug
1979; Taves 1968; Taves et al. 1976).
Compared with these previous assess-
ments, in the present study we analyzed a suf-
ficient sample size that facilitated the
characterization of the serum ﬂuorochemical
distribution by age and sex. This included the
calculation of estimates of upper tolerance
limits and their upper bounds. The highest
serum PFOS measurement (confirmed by
reassay of the sample) was 1,656 ppb. This
PFOS sample approximated the average serum
PFOS levels observed for POSF-related pro-
duction workers (Olsen et al. 1999, 2003a);
however, there is no POSF-related production
plant in the Portland area. Because donor
samples were anonymous, it is not possible to
Article | Olsen et al.
1896 VOLUME 111 | NUMBER 16 | December 2003 • Environmental Health Perspectives
Table 1. Measures of central tendency of serum ﬂuorochemical concentrations (ppb) for American Red Cross blood donors (n = 645) by sex.
PFOS PFOA PFHS PFOSAA M570
All (n = 645)
Range < LLOQ (4.3)–1656.0 < LLOQ (1.9)–52.3 < LLOQ (1.4)–66.3 < LLOQ (1.6)–60.1 < LLOQ (1.0)–16.4
IQR 24.7–48.5 3.4–6.6 < LLOQ (2.1)–3.4 < LLOQ (2.8)–3.4 < LLOQ (1.8)–2.2
< LLOQ (number) < 4.3 (1) < 1.9 (2) < 1.4 (72) < 1.6 (101) < 1.0 (63)
< 2.1 (48) < 2.1 (235) < 2.8 (271) < 1.8 (326)
Cumulative 90% 70.7 9.4 6.3 5.2 3.8
Median 35.8 4.7 1.5 < LLOQ (2.8) < LLOQ (1.8)
Geometric mean 34.9 4.6 1.9 2.0 1.3
95% CI geometric mean 33.3–36.5 4.3–4.8 1.8–2.0 1.9–2.1 1.3–1.4
Males (n = 332)
Range < LLOQ (4.3)–1656.0 < LLOQ (1.9)–29.0 < LLOQ (1.4)–66.3 < LLOQ (1.6)–60.1 < LLOQ (1.0)–16.4
IQR  28.3–49.7 3.6–7.0 < LLOQ (2.1)–3.8 < LLOQ (2.8)–3.3 < LLOQ (1.8)–2.2
< LLOQ (number) < 2.1 (19) < 1.4 (30) < 1.6 (58) < 1.0 (36)
< 2.1 (104) < 2.8 (146) < 1.8 (163)
Cumulative 90% 72.6 10.1 7.9 4.7 3.5
Median 37.4 4.9 2.1 < LLOQ (2.8) < LLOQ (1.8)
Geometric mean 37.8 4.9 2.2 1.9 1.3
95% CI geometric mean 35.5–40.3 4.6–5.3 2.0–2.4 1.8–2.1 1.2–1.4
Females (n = 313)
Range 6.0–226.0 < LLOQ (2.1)–52.3 < LLOQ (1.4)–15.3 < LLOQ (1.6)–27.6 < LLOQ (1.0)–10.6
IQR 22.0–45.8 3.1–6.2 < LLOQ (2.1)–2.8 < LLOQ (2.8)–3.6 < LLOQ (1.8)–2.2
< LLOQ (number) < 1.9 (2) < 1.4 (42) < 1.6 (43) < 1.0 (27)
< 2.1 (29) < 2.1 (131) < 2.8 (125) < 1.8 (163)
Cumulative 90% 69.7 8.4 5.0 6.1 4.0
Median 31.3 4.4 < LLOQ (2.1) < LLOQ (2.8) < LLOQ 1.8)
Geometric mean 32.1 4.2 1.6 2.1 1.3
95% CI geometric mean 30.0–34.3 3.9–4.5 1.5–1.8 2.0–2.3 1.2–1.4determine anything else about this individual
besides sex (male), age (67 years), and loca-
tion of the blood bank (Portland). The next
highest donor level for PFOS was considerably
lower at 329 ppb (also a male, 62 years of age,
from the Portland blood bank location), and
the next eight highest serum PFOS values
(range, 139–226 ppb) were measured in four
females and four males from the Charlotte
(n = 4), Hagerstown (n = 2), Los Angeles
(n = 1), and Minneapolis–St. Paul (n =1 )
blood bank centers.
There was a relatively narrow range of geo-
metric mean serum concentrations for the six
locations studied. Because no exposure data
were available, any explanation of the variation
of serum concentrations once adjusted for age
and sex, albeit small, between these locations
would only be speculation. As discussed above,
the pathways leading to the presence of PFOS
in human blood are not well characterized but
likely involve environmental exposure (3M
Company 2003; Hansen et al. 2002; Martin et
al. 2002; OECD 2002) to PFOS or to precur-
sor molecules and residual levels of PFOS or
PFOS precursors in industrial and commercial
products (3M Company 2003).
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Figure 2. Box and whisker plots of serum ﬂuorochemical concentrations by age and sex for (A) PFOS, (B) PFOA, (C) PFHS, (D) PFOSAA, (E) M570, and (F) total
ﬂuorochemicals. The boxes indicate the interquartile ranges of the natural log distributions; the circle within each box is the mean; the whiskers extend to the last
observation within 1.5 times the interquartile range; and the circles outside the whiskers represent observations outside the 1.5 × interquartile range.
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0.0Our findings showed a correlation
between PFOS and PFOA. PFOS has been
measured in both human populations and
wildlife, including marine mammals and 
piscivorous birds (3M Company 2003; Giesy
and Kannan 2001; Hansen et al. 2001;
Kannan et al. 2001a, 2001b, 2002a, 2002b).
Serum PFOA concentrations, however, have
been consistently quantified (i.e., measured
above the LLOQs) primarily in humans. This
association between PFOS and PFOA is of sig-
niﬁcant interest because PFOA cannot convert
directly from PFOS (or vice versa). Whether
this statistical association is due to the pres-
ence of PFOA as a by-product in POSF-
related production or to other nonrelated
environmental or consumer products (e.g.,
higher chain telomers) remains to be deter-
mined. Another unanswered question is
whether perfluorooctanesulfonamides can
metabolize in humans to PFOA.
PFOS was also correlated with two ﬂuoro-
chemicals, PFOSAA and M570. These ana-
lytes may come from oxidation of compounds
used in consumer products involving
paper/packaging and carpet/textile/upholstery
protectants, respectively.
As with any interpretation of data obtained
from a study population, questions arise regard-
ing how well the data represent the source pop-
ulation and the ability to generalize from the
information collected. We believe the donor
selection process used in this study likely
resulted in a reasonable representation of the
overall donor population that was providing
blood at the time when these donors were
sampled. Donors were not specifically
informed of the ﬂuorochemicals assayed, nor
was there any linkage between the sample col-
lected and personal identiﬁers. No information
was obtained about past exposure histories to
POSF-related chemistries and materials or the
other fluorochemicals that were analyzed.
Unlike other biomonitoring efforts of environ-
mental chemicals [Centers for Disease Control
and Prevention (CDC) 2003], it was not the
intent of this study design to be representative
of the diverse U.S. general adult population.
American Red Cross blood donors are a self-
selected group from the U.S. population (Allen
and Butler 1993; Andaleeb and Basu 1995;
Burnett 1982; Chiavetta et al. 2000; Leibrecht
et al. 1976; Oswalt 1977; Wood et al. 2001).
Motivations to donate blood may include
altruism, desire for personal credit, low self-
esteem, and social pressure. Donors in this
study did not include children or the elderly.
Future biomonitoring efforts by the National
Center for Environmental Health at the CDC
may analyze for PFOS and other ﬂuorochemi-
cals that will allow for a representative sample
analysis of the U.S. civilian population (Calafat
A. Personal communication).
A large body of toxicology and epidemiol-
ogy data is available for review regarding
PFOS (3M Company 2003; OECD 2002).
Briefly, PFOS concentrates primarily in the
liver and, to a lesser extent, in the plasma of
rats (Johnson et al. 1979). There appears to
be significant enterohepatic circulation of
PFOS with both urinary and fecal excretion
(Johnson et al. 1984). Studies in rodents and
primates suggest toxicity varies with cumula-
tive dose of PFOS (Butenhoff et al. 2002b;
Butenhoff and Seacat 2001; Grasty et al.
2002; Lau et al. 2003; Seacat et al. 2002b,
2002c; Thibodeaux et al. 2003; Thomford et
al. 2002). Lowered serum total cholesterol
appeared to be a consistent early ﬁnding, with
cumulative toxicity resulting in metabolic wast-
ing and ultimately death in laboratory animals
exposed to high doses. In cynomolgus mon-
keys, serum cholesterol levels began to decline
above 100 ppm serum PFOS concentrations
(Seacat et al. 2002c). The serum half-life of
elimination approximated 200 days at the end
of dosing (180 days, 0.75 mg/kg/day). An
interim analysis estimated the half-life of serum
elimination for PFOS in humans to be approxi-
mately 9 years (standard deviation = 6) based
on nine POSF-related production workers
(Burris et al. 2002). A 2-year feeding study of
PFOS in rats produced a modest liver tumor
response in the high-dose group (20 ppm
PFOS in feed) (Seacat et al. 2002a). A 2-year
feeding study of N-EtFOSE provided compa-
rable ﬁndings (Thomford et al. 2002). PFOS
and N-EtFOSE are not genotoxic in standard
tests (3M Company 2003). The mechanisms
of toxicity are not fully understood but may
include effects on fatty acid transport and
metabolism, membrane function, and/or mito-
chondrial bioenergetics (Berthiaume and
Wallace 2002; Hu et al. 2002; Luebker et al.
2002; O’Brien and Wallace 2002; Starkov and
Wallace 2002). PFOS caused modest peroxi-
some proliferation in rats (Berthiaume and
Wallace 2002; Seacat et al. 2002b). Medical
surveillance of POSF production employees
has not been associated with adverse clinical
chemistry or hematology results (Olsen et al.
1999, 2003a). A retrospective cohort mortality
study of this production workforce reported an
excess of bladder cancer based on three deaths
compared with 0.2 expected (Alexander et al.
2003). It was not determined whether this
association was PFOS-related or possibly due
to other occupational exposures or nonoccupa-
tional exposures. Whether this is a biologically
plausible association with PFOS is question-
able, as PFOS did not produce bladder or
other urinary tract toxicity in rat or primate
chronic or subchronic studies (Seacat et al.
2002a, 2002b, 2002c). PFOS is not likely to
be insoluble in human urine (solubility,
305 µg/mL at 23–24°C) at the serum concen-
trations present in these workers (Ellefson
2001). In a review article, Cohen (1998)
reported that all of the chemical agents listed as
known bladder cancer agents were genotoxic
and had metabolites that were genotoxic or
precipitated in the urine.
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Table 3. Age- and sex-adjusted mean and 95% CIs of serum ﬂuorochemical concentration (ppb) for the six American Red Cross blood bank locations.
PFOS PFOA PFHS PFOSAA M570 TOF
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Los Angeles 35.0 (33.4–36.5) 4.6 (4.4–4.8) 1.9 (1.8–2.0) 2.0 (1.9–2.2) 1.3 (1.3–1.4) 30.2 (29.0–31.3)
Portland 32.8 (30.5–34.2) 4.3 (4.0–4.4) 1.8 (1.7–2.0) 2.1 (2.0–2.3) 1.3 (1.2–1.4) 28.5 (26.7–30.4)
Minneapolis–St. Paul 34.8 (31.9–36.3) 4.5 (4.1–4.7) 1.8 (1.6–2.0) 1.8 (1.7–2.1) 1.3 (1.1–1.4) 29.7 (27.4–32.1)
Charlotte 39.0 (36.2–40.7) 5.0 (4.6–5.1) 2.2 (2.0–2.4) 2.1 (1.9–2.4) 1.4 (1.3–1.5) 33.4 (31.3–35.7)
Hagerstown 34.9 (32.8–36.5) 4.5 (4.2–4.6) 1.9 (1.8–2.1) 1.9 (1.8–2.1) 1.3 (1.2–1.4) 30.1 (28.4–31.9)
Boston 29.0 (26.0–30.3) 5.3 (4.6–5.6) 1.9 (1.7–2.3) 1.6 (1.4–1.8) 1.3 (1.2–1.5) 26.4 (23.9–29.2)
Table 2. Measures of central tendency of serum PFOS concentrations (ppb) by the six American Red Cross blood bank locations.
Los Angeles Portland Minneapolis–St. Paul Charlotte Hagerstown Boston
(n = 125) (n = 107) (n = 100) (n = 96) (n = 108) (n = 109)
Range 6.6–205.0 6.0–1656.0 7.7–207.0 19.3–166.0 7.6–226.0 < LLOQ (4.3)–87.2
IOR 29.5–53.7 17.2–37.7 23.9–43.3 36.3–70.9 24.4–48.1 20.8–39.1
90th percentile 70.1 49.4 71.7 105.3 69.8 48.7
Median 42.2 26.0 31.7 48.9 35.7 29.5
Geometric mean 40.4 27.0 33.1 51.5 35.3 28.0
95% CI geometric mean 37.0–44.0 23.5–31.1 29.8–36.7 46.8–56.8 31.8–39.2 25.4–31.0Given the consistency of the data ana-
lyzed, we hypothesize that the average serum
PFOS concentrations in nonoccupational
adult populations may range from 30 to
40 ppb, with 95% of a population’s serum
PFOS concentrations below 100 ppb. After
consideration of serum and liver PFOS con-
centrations associated with no-observed-
adverse-effect levels (NOAELs) and those
associated with benchmark dose values from
various toxicology studies, protective values
[i.e., benchmark internal concentrations
(BMICs)] were chosen as “points of departure”
for risk characterization (3M Company 2003).
For serum PFOS comparisons, the lower 95%
conﬁdence limit of the BMIC (5% response),
31 ppm, was chosen based on rat pup weight
gain during lactation (3M Company 2003).
Although rat pup weight gain was considered
the most sensitive end point, comparisons were
also made for other end points. For liver toxic-
ity, a serum PFOS concentration of 44 ppm
was associated with the NOAEL (3M
Company 2003; Seacat et al. 2002b). For liver
tumors in male and female rats, the lower 95%
conﬁdence limit of the BMIC (10% response),
62 ppm, was calculated (3M Company 2003).
Therefore, for these points of departure, a
human serum concentration of 100 ppb (the
upper bound estimate of the 95th percentile
observed in the present study) was associated
with margins of exposure of 310, 440, and
620, respectively (3M Company 2003). When
interpreting the signiﬁcance of these margins of
exposure, it should be noted that they are
based on the use of an internal dose (concen-
tration) of a compound that is not metabolized
and poorly eliminated. These facts reduce the
uncertainty in considering intraspecies or inter-
species response variability based on either
toxicokinetic or toxicodynamic factors.
PFOA was the other fluorochemical
assayed in the present study for which there are
considerable toxicology and epidemiology data
(Kennedy et al. In press). Sex and species dif-
ferences exist in the elimination of PFOA.
PFOA is rapidly cleared (hours) in female rats
compared with clearance in approximately
1 week in male rats (DuPont Haskell
Laboratory 1982; Hanhijarvi and Ylinen
1988; Johnson and Ober 1980). In addition
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Table 5. Estimates (ppb) of upper tolerance limits
and their upper 95% confidence limits for five
serum ﬂuorochemicals and a calculated TOF value. 
Upper Upper 95%
tolerance conﬁdence 
Fluorochemical limit Estimate limit
PFOS 90% 70.7 74.3
95% 88.5 100.0
99% 157.3 207.0
PFOA 90% 9.4 10.1
95% 12.1 13.6
99% 19.8 25.8
PFHS 90% 6.3 7.0
95% 9.5 10.8
99% 17.0 22.4
PFOSAA 90% 5.3 5.9
95% 7.6 8.5
99% 19.4 27.6
M570 90% 3.7 4.0
95% 5.0 5.4
99% 8.1 10.3
TOF 90% 59.9 63.1
95% 75.1 80.9
99% 137.3 187.5
Table 4. Relationship between PFOS concentration
and PFOSAA and M570 (Model 1), PFOA (Model 2),
or PFHS (Model 3) adjusted for age and sex.
Model Coefﬁcient 95% CI
Model 1a
Intercept 2.323 2.167–2.481
PFOSAA 0.544 0.473–0.619
M570 0.288 0.187–0.389
Age –0.011 –0.039–0.020
Sex 0.198 0.116–0.282
Model 2b
Intercept 2.575 2.412–2.723
PFOA 0.591 0.527–0.655
Age –0.010 –0.010–0.016
Sex 0.074 0.005–0.143
Model 3c
Intercept 3.252 3.073–3.408
PFHS 0.267 0.213–0.317
Age –0.008 –0.030–0.029
Sex 0.087 0.017–0.181
aln[PFOS] = ln([PFOSAA]a + [M570]b) + (c × age) + (d × sex) +
g + ε, where the serum concentration of the ﬂuorochemical
is shown in brackets and ε is the error term. bln[PFOS] =
ln[PFOA]a +( c × age) + (d × sex) + g + ε. c ln[PFOS] =
ln[PFHS]a + (c × age) + (d × sex) + g + ε.
Figure 3. Scatter plots (log scale) of associations between serum fluorochemical concentrations for
(A) PFOS and PFOA, (B) PFOS and PFHS, (C) PFOS and PFOSAA, (D) PFOS and M570, (E) PFOSAA and M570,
and (F) PFOA and PFHS.
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to urinary excretion, biliary excretion and reab-
sorption of PFOA occur (Johnson et al. 1984).
In the primate, the terminal phase elimination
half-life in serum for both sexes was approxi-
mately 1 month (Butenhoff et al. 2002a). An
interim analysis estimated the half-life of serum
elimination for PFOA in humans to be
approximately 4 years (standard deviation, 4)
(Burris et al. 2002). The liver is a primary tar-
get organ for toxicity. In rats, administration of
the ammonium salt of PFOA (APFO) resulted
in peroxisome proliferation, uncoupling of
mitochondrial oxidative phosphorylation,
increased mitochondrial DNA copy number,
and altered lipid metabolism (Berthiaume and
Wallace 2002; Haughom and Spydevold 1992;
Keller et al. 1992). Rats fed a diet of 300 ppm
PFOA (daily dose of 15 mg/kg/day) had
increased incidences of liver, Leydig cell, and
pancreas acinar cell adenomas (Biegel et al.
2001). The tumors likely occurred via
nongenotoxic mechanisms. Peroxisome prolif-
eration may account for the increase in liver
tumors. Enhanced hepatic aromatase activity
resulting in increased estradiol may account
for the Leydig cell tumors (Biegel et al. 1995,
2001; Cook et al. 1992, 1999). The pancreas
acinar cell tumors were hypothesized to be a
result of a mild but sustained increase in
plasma cholecystokinin levels secondary to
hepatic cholestasis (Biegel et al. 2001; Obourn
et al. 1997). Changes in plasma cholecysto-
kinin have not been observed in primates or
humans exposed to APFO (Butenhoff et al.
2002a; Olsen et al. 2000). Hepatic toxicity,
hypolipidemia, and abnormal hormone levels
have not been associated with serum PFOA
concentrations in APFO production workers
whose serum levels have averaged 5 ppm with
a range of and 0.1–114 ppm (Gilliland and
Mandel 1996; Olsen et al. 1998, 2000). A
retrospective cohort mortality study of APFO
production workers did not report statistically
significant increased standardized mortality
ratios for liver cancer, cirrhosis of the liver, or
pancreas cancer, although an association was
observed with prostate cancer mortality and
nonspeciﬁc job duration of at least 10 years in
the chemical plant (Gilliland and Mandel
1993). This association with prostate cancer
mortality, however, was not observed in an
updated study that used an exposure matrix
specific to APFO production activities
(Alexander 2001).
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